Fernanda Peria

Prof. Dr. Fernanda Peria

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2015 in Journal of Cancer Education
Verified
Journal Article
Closed access
PDF file
DCDaniel de Iracema Gomes Cubero
Daniel de Iracema Gomes Cubero
RFRenata Rego Lins Fumis
Renata Rego Lins Fumis
TSThiago Herick de Sa
Thiago Herick de Sa
ADAldo Dettino
Aldo Dettino
FCFelipe Osório Costa
Felipe Osório Costa
AGAuro del Giglio
Auro del Giglio

13 April 2016 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
KRKaren Bento Ribeiro
Karen Bento Ribeiro
JZJuliana da Silva Zanetti
Juliana da Silva Zanetti
ARAlfredo Ribeiro-Silva
Alfredo Ribeiro-Silva
LRLiane Rapatoni
Liane Rapatoni
HOHarley Francisco de Oliveira
Harley Francisco de Oliveira
FPFernanda Peria
Fernanda Peria
INTRODUCTION: Multiple stages of carcinogenesis in colon cancer encompass subpopulations of cancer stem cells (CSC), responsible for tumor cell transformation, growth and proliferation. CD44 and CD166 proteins are CSC markers associated with cell sig

12 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
OAOlga Laura Sena Almeida
Olga Laura Sena Almeida
EFEduardo Ferriolli
Eduardo Ferriolli
RTRoberta Cristina Cintra Taveira
Roberta Cristina Cintra Taveira
MRMeire Gallo Rosenburg
Meire Gallo Rosenburg
DCDaniela Dalpubel Campanari
Daniela Dalpubel Campanari
NLNereida K. C. Lima
Nereida K. C. Lima
This study compared mirtazapine with megestrol in the management of cancer-related anorexia–cachexia syndrome in patients with advanced cancer. A randomized, double-blind, controlled clinical trial involving patients with advanced cancer and anorexia–cachexia syndrome was performed. Participants received mirtazapine 30 mg/day or megestrol 320 mg/day for eight weeks. The primary endpoint was the effect of mirtazapine on weight gain and the secondary endpoints were its effect on appetite, muscle strength, physical performance, body composition, adverse events, and medication adherence. Linear regression model with mixed effects was applied and a significance level of 5% was adopted. Fifty-two patients were randomized. Mean age was 65.8 ± 8.4 years. There was weight gain in 52% of the participants in the megestrol group and in 38% in the mirtazapine group after four weeks (p = 0.040). Appetite improved in 92% of the participants in the megestrol group and in 56% in the mirtazapine group after eight weeks (p = 0.007). In the sub-analysis by sex, women showed improvement in appetite (p < 0.001) and weight gain (p < 0.005) in the mirtazapine group, which was not observed in men. Mirtazapine appears to be inferior to megestrol in weight and appetite improvement. However, there may be a difference in the therapeutic response between sexes.

1 January 2012 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
KRK.B. Ribeiro
K.B. Ribeiro
CMC.H. Miranda
C.H. Miranda
JAJ.M. Andrade
J.M. Andrade
LGL.G. Galli
L.G. Galli
DTDaniel Guimarães Tiezzi
Daniel Guimarães Tiezzi
FPFernanda Peria
Fernanda Peria
Trastuzumab is an important biological agent in the treatment of HER2-positive breast cancer, with effects on response rates, progression-free survival, overall survival and quality of life. Although this drug is well tolerated in terms of adverse effects, trastuzumab-associated myocardiotoxicity has been described to have an incidence of 0.6–4.5% and in rare cases, the drug can trigger severe congestive heart failure with progression to death or even mimic acute coronary syndrome with complete left bundle branch blockade. In this paper is reported a case of trastuzumab-associated myocardiotoxicity manifesting as acute coronary syndrome in a 69-year-old female. The patient is currently undergoing a conservative clinical treatment that restricts overexertion.The majority of clinical studies report trastuzumab-induced cardiotoxicity as a rare event, and, when present, characterized by mild to moderate clinical signs, the ease of reversibility with pharmacological measures and the temporary discontinuation of the medication. Conversely, it is vital for the oncologist/cardiologist to consider the possibility that trastuzumab-induced cardiotoxicity may manifest itself as a severe clinical case, mimicking acute coronary syndrome, justifying careful risk stratification and adequate cardiac monitoring, especially in high-risk patients.

17 October 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AUAndrea Queiróz Ungari
Andrea Queiróz Ungari
LPLeonardo Pereira
Leonardo Pereira
ANAltacilio Aparecido Nunes
Altacilio Aparecido Nunes
FPFernanda Peria
Fernanda Peria
Metastatic colorectal cancer imposes a substantial burden on patients and society. Over the last years, progresses in the treatment have been made especially due to the introduction of monoclonal antibodies, such as bevacizumab which, on the other hand, has considerably increased the costs of treatment. We performed a cost-effectiveness analysis of bevacizumab plus XELOX in comparison with XELOX alone in metastatic colorectal cancer in first-line therapy, from the perspective of a public hospital school in Brazil. This was a cost-effectiveness analysis performed by a decision tree and Markov models. Costs were expressed in local currency and outcomes were expressed in months of life gained. The model was constructed using the TreeAge Pro 2013® software. The incremental difference in years of life gained was 2.25 months, with an extra cost of 47,833.57 BRL, resulting in an incremental cost-effectiveness of 21,231.43 BRL per month of life gained. Although the XELOX plus bevacizumab regimen is a more expensive and more effective treatment than XELOX, it does not fit the reimbursement values fixed by the public healthcare system in Brazil.

10 July 2020 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
FTFelipe Amstalden Trevisan
Felipe Amstalden Trevisan
ARAndressa Romualdo Rodrigues
Andressa Romualdo Rodrigues
FNFermino Sanches Lizarte Neto
Fermino Sanches Lizarte Neto
FPFernanda Peria
Fernanda Peria
MCMúcio Luiz de Assis Cirino
Múcio Luiz de Assis Cirino
CJCarlos Gilberto Carlotti Júnior
Carlos Gilberto Carlotti Júnior
Aim: To evaluate the effect of radiotherapy and temozolomide on the expression of miRNAs apoptotic (miRNAs-21, -221, -222 (anti-apoptotic) and miRNAs-15a, -16 (pro-apoptotic)) and the gene MGMT in glioblastoma cell lines. Background: The limited knowledge of the molecular biology of malignant gliomas may hinder the development of therapeutic modalities. In this scenario, one of the greatest advances of recent years was the identification of microRNAs. These molecules have an important role in biological processes involving cancer, including glioblastoma. Materials and methods Trypan blue was used to verify the cell viability, and real time PCR to quantify the expression of microRNAs and gene 24, 48 and 120 h after exposure to treatments. Results: There was a statistically significant decrease of expression of miR-15a between 48 and 120 h in line T98 G treated with radiation, increased expression of miR-15a between 24 and 120 h in line U251 treated with radiation and temozolomide, and increased expression of miR-16 between 24 and 120 h in line U251 treated with radiation alone and when combined with temozolomide. There was a decrease in MGMT gene expression, between 24 and 48 h in U343 cells treated with temozolomide. Conclusions: Ionizing radiation and temozolomide modified the expression of miRNAs studied and MGMT.